THE MOBILE INSULIN TITRATION INTERVENTION PROGRAM TO TRANSITION FROM BASAL INSULIN TO A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (MITI-GLP1): USING DAILY SMS TEXT MESSAGES AND WEEKLY PHONE CALLS TO TRANSITION PRIMARY CARE PATIENTS WITH WELL-CONTROLLED TYPE 2 DIABETES FROM BASAL INSULIN TO A GLP1-RA

被引：0
|
作者：
Levy, Natalie K. [1 ]
Nerlino, Katie [1 ]
Bongalos, Sherlane B. [2 ]
Dasilva, Alexis [2 ]
Uzor, Chinye N. [2 ]
Sonubi, Olubunmi O. [2 ]
机构：
[1] NYU, Bellevue Hosp, Med, Sch Med, New York, NY USA
[2] Bellevue Hosp Ctr, Med, New York, NY USA
来源：
JOURNAL OF GENERAL INTERNAL MEDICINE | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页码：S637 / S637
页数：1
相关论文
共 46 条
  • [21] A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes
    Baxter, Mike
    Morimoto, Yukiko
    Tamiwa, Masami
    Hattori, Masakatsu
    Peng, Xuejun Victor
    Lubwama, Robert
    Maegawa, Hiroshi
    DIABETES THERAPY, 2020, 11 (07) : 1481 - 1496
  • [22] A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes
    Mike Baxter
    Yukiko Morimoto
    Masami Tamiwa
    Masakatsu Hattori
    Xuejun Victor Peng
    Robert Lubwama
    Hiroshi Maegawa
    Diabetes Therapy, 2020, 11 : 1481 - 1496
  • [23] Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening
    Rosenstock, Julio
    Blonde, Lawrence
    Aroda, Vanita R.
    Frias, Juan
    Souhami, Elisabeth
    Ji, Chen
    Niemoeller, Elisabeth
    Del Prato, Stefano
    DIABETES OBESITY & METABOLISM, 2021, 23 (06): : 1331 - 1341
  • [24] Efficacy and Safety of Once-Weekly Insulin Icodec vs. Once-Daily Basal Insulin in Type 2 Diabetes according to Baseline Glucagon-Like Peptide 1 Receptor Agonist Use-ONWARDS 1-5
    Vilsboll, Tina
    Bangsgaard, Katrine O.
    Fu, Ariel
    Kellerer, Monika
    Sogaard, Stinne B.
    Goldenberg, Ronald
    DIABETES, 2024, 73
  • [25] Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: A longitudinal study of a US administrative claims database
    Tong, Liyue
    Pan, Chunshen
    Wang, Hongwei
    Bertolini, Monica
    Lew, Elisheva
    Meneghini, Luigi F.
    DIABETES OBESITY & METABOLISM, 2018, 20 (04): : 831 - 839
  • [26] Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro
    Rosenstock, Julio
    Fonseca, Vivian A.
    Gross, Jorge L.
    Ratner, Robert E.
    Ahren, Bo
    Chow, Francis C. C.
    Yang, Fred
    Miller, Diane
    Johnson, Susan L.
    Stewart, Murray W.
    Leiter, Lawrence A.
    DIABETES CARE, 2014, 37 (08) : 2317 - 2325
  • [27] Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes
    Blonde, Lawrence
    Anderson, John E.
    Chava, Pavan
    Dendy, Jared A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (05) : 793 - 804
  • [28] Adding rapid-acting insulin or GLP-1 receptor agonist to basal insulin in patients with type 2 diabetes: real-world health care costs from a US managed care setting
    Dalal, M.
    Xie, L.
    Baser, O.
    DiGenio, A.
    DIABETOLOGIA, 2013, 56 : S358 - S358
  • [29] A randomized trial comparing the efficacy and safety of treating patients with type 2 diabetes and highly elevated HbA1c levels with basal-bolus insulin or a glucagon-like peptide-1 receptor agonist plus basal-bolus insulin: The SIMPLE study
    Abreu, Marconi
    Tumyan, Anna
    Elhassan, Ahmed
    Peicher, Katherine
    Papacostea, Olivia
    Dimachkie, Perihan
    Siddiqui, Muhammad S.
    Pop, Laurentiu M.
    Gunasekaran, Uma
    Meneghini, Luigi F.
    Adams-Huet, Beverley
    Li, Xilong
    Lingvay, Ildiko
    DIABETES OBESITY & METABOLISM, 2019, 21 (09): : 2133 - 2141
  • [30] Treatment intensification following glucagon-like peptide-1 receptor agonist in type 2 diabetes: Comparative effectiveness analyses between free vs. fixed combination of GLP-1 RA and basal insulin. RESTORE-G real-world study
    Candido, Riccardo
    Nicolucci, Antonio
    Larosa, Monica
    Rossi, Maria Chiara
    Napoli, Raffaele
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2024, 34 (08) : 1846 - 1853
12345